| __timestamp | Blueprint Medicines Corporation | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 2917513 |
| Thursday, January 1, 2015 | 14456000 | 7878291 |
| Friday, January 1, 2016 | 19218000 | 8366794 |
| Sunday, January 1, 2017 | 27986000 | 6610381 |
| Monday, January 1, 2018 | 47928000 | 6556000 |
| Tuesday, January 1, 2019 | 96388000 | 6930000 |
| Wednesday, January 1, 2020 | 157743000 | 8758000 |
| Friday, January 1, 2021 | 195293000 | 10806000 |
| Saturday, January 1, 2022 | 237374000 | 9844000 |
| Sunday, January 1, 2023 | 295141000 | 13481000 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial. This chart highlights the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Soleno Therapeutics, Inc. over the past decade.
Blueprint Medicines has seen a staggering increase in SG&A expenses, growing from approximately $7.9 million in 2014 to nearly $295 million in 2023. This represents a growth of over 3,600%, reflecting the company's aggressive expansion and investment in its operations. In contrast, Soleno Therapeutics has maintained a more conservative growth in expenses, with a 362% increase from around $2.9 million in 2014 to $13.5 million in 2023.
This divergence in financial strategy underscores the different paths these companies have taken in their quest for innovation and market leadership. Understanding these trends provides valuable insights into their operational priorities and future trajectories.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Soleno Therapeutics, Inc.
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Cost Management Insights: SG&A Expenses for Jazz Pharmaceuticals plc and Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
Blueprint Medicines Corporation vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends